BEXIMCO PHARMA.GDR REGS 1 Total Liabilities
BEXIMCO PHARMA.GDR REGS 1 total liabilities. Based on the latest financial reports, BEXIMCO PHARMA.GDR REGS 1 (R2WA) has total liabilities worth €20.17 Billion EUR (≈ $23.58 Billion USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check R2WA asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of BEXIMCO PHARMA.GDR REGS 1 (2021–2024)
Total liabilities of BEXIMCO PHARMA.GDR REGS 1 from 2021 to 2024. This chart illustrates how BEXIMCO PHARMA.GDR REGS 1's total liabilities have evolved over time, based on quarterly financial data.
BEXIMCO PHARMA.GDR REGS 1 Competitors by Total Liabilities
The table below lists competitors of BEXIMCO PHARMA.GDR REGS 1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Investcorp Europe Acquisition I Corp
NASDAQ:IVCB
|
USA | $10.09 Million |
|
Toubani Resources Ltd
AU:TRE
|
Australia | AU$8.92 Million |
|
EBEST Investment & Securities Co. Ltd
KQ:078020
|
Korea | ₩13.46 Trillion |
|
WildBrain Ltd
TO:WILD
|
Canada | CA$796.01 Million |
|
Wooriro Co. Ltd
KQ:046970
|
Korea | ₩17.68 Billion |
|
Genesis Technology
TWO:6221
|
Taiwan | NT$2.80 Billion |
|
Gamania Digital Entertainment Co Ltd
TWO:6180
|
Taiwan | NT$3.62 Billion |
|
Taisun Enterprise Co Ltd
TW:1218
|
Taiwan | NT$2.44 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down BEXIMCO PHARMA.GDR REGS 1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BEXIMCO PHARMA.GDR REGS 1 balance sheet assets.
Liquidity & Leverage Metrics
BEXIMCO PHARMA.GDR REGS 1 Total Liabilities Ratios Explained
BEXIMCO PHARMA.GDR REGS 1 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BEXIMCO PHARMA.GDR REGS 1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BEXIMCO PHARMA.GDR REGS 1 (2021–2024)
The table below shows the annual total liabilities of BEXIMCO PHARMA.GDR REGS 1 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-06-30 | €17.44 Billion ≈ $20.39 Billion |
-19.02% |
| 2023-06-30 | €21.54 Billion ≈ $25.18 Billion |
+0.12% |
| 2022-06-30 | €21.51 Billion ≈ $25.15 Billion |
+44.56% |
| 2021-06-30 | €14.88 Billion ≈ $17.40 Billion |
-- |
About BEXIMCO PHARMA.GDR REGS 1
Beximco Pharmaceuticals PLC. manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskelet… Read more